Transactivation and Inhibitory Domains of Hypoxia-inducible Factor 1α

MODULATION OF TRANSCRIPTIONAL ACTIVITY BY OXYGEN TENSION*

  1. Bing-Hua Jiang,
  2. Jenny Z. Zheng,
  3. Sandra W. Leung,
  4. Rick Roe and
  5. Gregg L. Semenza
  1. From the Center for Medical Genetics, Departments of Pediatrics and Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-3914

    Abstract

    Hypoxia-inducible factor 1 (HIF-1) binds to cis-acting hypoxia-response elements within the erythropoietin, vascular endothelial growth factor, and other genes to activate transcription in hypoxic cells. HIF-1 is a basic helix-loop-helix transcription factor composed of HIF-1α and HIF-1β subunits. Here, we demonstrate that HIF-1α contains two transactivation domains located between amino acids 531 and 826. When expressed as GAL4 fusion proteins, the transcriptional activity of these domains increased in response to hypoxia. Fusion protein levels were unaffected by changes in cellular O2 tension. Two minimal transactivation domains were localized to amino acid residues 531–575 and 786–826. The transcriptional activation domains were separated by amino acid sequences that inhibited transactivation. Deletion analysis demonstrated that the gradual removal of inhibitory domain sequences (amino acids 576–785) was associated with progressively increased transcriptional activity of the fusion proteins, especially in cells cultured at 20% O2. Transcriptional activity of GAL4/HIF-1α fusion proteins was increased in cells exposed to 1% O2, cobalt chloride, or desferrioxamine, each of which also increased levels of endogenous HIF-1α protein but did not affect fusion protein levels. These results indicate that increased transcriptional activity mediated by HIF-1 in hypoxic cells results from both increased HIF-1α protein levels and increased activity of HIF-1α transactivation domains.

    Footnotes

    • * This work was supported in part by grants from the American Heart Association and the National Institutes of Health (R01-DK39869 and R01-HL55338).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Established Investigator of the American Heart Association. To whom correspondence should be addressed: The Johns Hopkins Hospital, CMSC-1004, 600 N. Wolfe St., Baltimore, MD 21287-3914. Tel.: 410-955-1619; Fax: 410-955-0484; E-mail:gsemenza{at}welchlink.welch.jhu.edu.

    • 1  The abbreviations used are: EPO, erythropoietin; VEGF, vascular endothelial growth factor; HIF-1, hypoxia-inducible factor 1; HRE, hypoxia-response element; EMSA, electrophoretic mobility shift assay; TAD, transactivation domain; ID, inhibitory domain.

      • Received November 6, 1996.
      • Revision received April 25, 1997.
    « Previous | Next Article »Table of Contents
    • Advertisement
    • Advertisement
    Advertisement